Jineetkumar Gawad

Dr. Jineetkumar Gawad

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2018 in BMC Chemistry
Verified
Journal Article
Open access
PDF file
JGJineetkumar Gawad
Jineetkumar Gawad
CBChandrakant Bonde
Chandrakant Bonde
Tuberculosis has proved harmful to the entire history of mankind from past several decades. Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1) is a recent target which was identified in 2009 but unfortunately it is neither explored nor crossed phase II. In past several decades few targets were identified for effective antitubercular drug discovery. Resistance is the major problem for effective antitubercular drug discovery. Arabinose is constituent of mycobacterium cell wall. Biosynthesis of arabinose is FAD dependant two step epimerisation reaction which is catalysed by DprE1 and DprE2 flavoprotein enzymes. The current review is mainly emphases on DprE1 as a perspective challenge for further research.

1 January 2018 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
JGJineetkumar Gawad
Jineetkumar Gawad
CBChandrakant Bonde
Chandrakant Bonde

19 December 2018 in BMC Chemistry
Verified
Journal Article
Open access
PDF file
JGJineetkumar Gawad
Jineetkumar Gawad
CBChandrakant Bonde
Chandrakant Bonde
Tuberculosis is an air-borne disease, mostly affecting young adults in their productive years. Here, Ligand-based drug design approach yielded a series of 23 novel 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine derivatives. The required building block of imidazopyridine was synthesized from commercially available 5,5-diaminopyridine-3-ol followed by four step sequence. Derivatives were prepared using various substituted aromatic aldehydes. All the synthesized analogues were characterized using NMR, Mass analysis and also screened for in vitro antitubercular activity against Mycobacterium tuberculosis (H37Rv). Four compounds, 5c (MIC-0.6 μmol/L); 5g (MIC-0.5 μmol/L); 5i (MIC-0.8 μmol/L); and 5u (MIC-0.7 μmol/L) were identified as potent analogues. Drug receptor interactions were studied with the help of ligand docking using maestro molecular modeling interphase, Schrodinger. Here, computational studies showed promising interaction with other residues with good score, which is novel finding than previously reported. So, these compounds may exhibit in vivo DprE1 inhibitory activity.

25 January 2025 in Journal of the Taiwan Institute of Chemical Engineers
Verified
Journal Article
Closed access
MTMuhammad Tanveer
Muhammad Tanveer
MQM.A Qadeer
M.A Qadeer
AAAhmad Ruhan Ali
Ahmad Ruhan Ali
JGJineetkumar Gawad
Jineetkumar Gawad
HCHusnain Haider Cheema
Husnain Haider Cheema
ABAbdulaziz Bentalib
Abdulaziz Bentalib

1 August 2019 in Synthetic Communications
Verified
Journal Article
Closed access
JGJineetkumar Gawad
Jineetkumar Gawad
CBChandrakant Bonde
Chandrakant Bonde
Tuberculosis (TB) is an infectious disease and caused by various strains of mycobacteria. In the present study, pharmacophore model was developed using single ligand by ligand-based drug discovery approach. The key features responsible for DprE1 inhibitory activity were taken into consideration for developing pharmacophore. After the virtual screening, top 1000 hits were further subjected to docking study using GLIDE module, Schrödinger. Docking studies have shown promising interaction with amino residues with better glide score. Ligand-based drug design approach yielded a series of 15, 2-(6-nitrobenzo[d]thiazol-2-ylthio)-N-benzyl-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide derivatives. All synthesized derivatives were characterized using NMR, mass, CHN analysis. The synthesized compounds were screened for In vitro antitubercular activity against Mycobacterium tuberculosis (H37Rv). Four compounds, 5g (MIC-1.01 μM); 5i (MIC-0.91 μM); 5k (MIC-0.82 μM); and 5o (MIC-1.04 μM) has shown promising activity compared to MIC of standard isoniazid (INH) and DprE1 enzyme inhibition was compared to BTZ043. Two halogen-substituted compounds have exhibited drastic enzyme inhibition. GRAPHICAL ABSTRACT

1 October 2022 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
CBChandrakant Bonde
Chandrakant Bonde
JGJineetkumar Gawad
Jineetkumar Gawad
SBSmita Bonde
Smita Bonde